A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Durvalumab is a new type of drug for many kinds of cancer. It is considered "immunotherapy"
and not "chemotherapy". Laboratory tests show that it works by allowing the immune system to
detect cancer and reactivate the immune response. This may help to slow down the growth of
cancer or may cause cancer cells to die. Durvalumab has been shown to shrink tumours in
animals and has been studied in more than 5000 people and seems promising.
Tremelimumab is a new type of drug for various types of cancers. It works in a similar way
to durvalumab and may improve the effect of durvalumab. Tremelimumab may also help slow the
growth of the cancer cells or may cause cancer cells to die. It has been shown to shrink
tumours in animals and has been studied in over 1200 people and seems promising.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society